Related Experiment Video
Updated: May 22, 2026
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Biological markers of cisplatin resistance in advanced testicular germ cell tumours
Adelaida García-Velasco1, Ignacio Durán, Elena García
1Centro Integral Oncológico Clara Campal, Hospital Norte de Madrid Sanchinarro, C/ Oña, 10, ES-28050 Madrid, Spain. adelaidagarcia@hospitaldemadrid.com
Introduction:
Germ cell tumours (GCTs) of the testis show exquisite sensitivity to treatment with cisplatin. Despite the high cure rates provided by platinum-based chemotherapy, 10-20% of patients die from progressive disease. Although various cellular pathways may influence cisplatin efficacy, their actual impact has not been comprehensively investigated in advanced GCTs. The objective of the present study was to clarify the role of the expression status of proteins involved in the Rb and p53 tumour suppressor pathways in sensitivity and resistance of GCTs to cisplatin-based chemotherapy.
Materials And Methods:
Paraffin-embedded tumour tissues from 84 patients with advanced GCT treated with cisplatin-based chemotherapy were analysed. Immunohistochemical expression of proteins p53 and mdm2, and the G1-phase cyclins D1 and D2 (CD1 and CD2) was assessed and correlated with the clinical course.
Results:
The percentages of positive expression of p53, mdm2, CD1 and CD2 were 56, 57, 37.5 and 55%, respectively. From univariate analysis, there was no significant association between p53, mdm2 or CD1 expression and outcome. Instead, positive CD2 expression was found to be marginally associated with shorter median duration of progression-free survival (PFS) (p=0.06). In multivariate analysis, none of the molecular markers retained statistical significance with treatment response or survival.
Conclusions:
Tissular expression of p53, mdm2 and CD1 is not associated with prognosis or treatment response in patients with advanced GCT. Aberrant CD2 expression appears to further determine a shorter PFS. Larger and further studies are required to validate CD2 as a marker of cisplatin resistance.
Insights
Cisplatin chemotherapy is effective for testicular germ cell tumors (GCTs), but resistance occurs. This study found p53, mdm2, and cyclin D1 (CD1) expression did not predict treatment outcomes, while aberrant cyclin D2 (CD2) expression suggested shorter progression-free survival in advanced GCTs.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Testicular germ cell tumors (GCTs) are highly sensitive to cisplatin chemotherapy, yet 10-20% of patients experience treatment failure.
- The molecular mechanisms underlying cisplatin resistance in advanced GCTs remain incompletely understood.
- Investigating the role of tumor suppressor pathways, specifically Rb and p53, is crucial for understanding treatment response.
Purpose of the Study:
- To investigate the association between the expression of p53, mdm2, and G1-phase cyclins D1 (CD1) and D2 (CD2) and cisplatin sensitivity in advanced GCTs.
- To determine if these molecular markers can predict treatment response and clinical outcomes in patients with advanced GCTs.
Main Methods:
- Immunohistochemical analysis of p53, mdm2, CD1, and CD2 expression in tumor tissues from 84 patients with advanced GCT.
- Correlation of protein expression levels with clinical data, including treatment response and survival outcomes.
- Statistical analysis using univariate and multivariate models to assess the significance of molecular markers.
Main Results:
- Positive expression rates for p53, mdm2, CD1, and CD2 were 56%, 57%, 37.5%, and 55%, respectively.
- No significant association was found between p53, mdm2, or CD1 expression and patient prognosis or treatment response.
- Aberrant CD2 expression showed a marginal association with shorter progression-free survival (PFS) in univariate analysis (p=0.06).
Conclusions:
- Expression of p53, mdm2, and CD1 does not appear to be a reliable prognostic or predictive biomarker for cisplatin treatment in advanced GCTs.
- Aberrant CD2 expression may indicate a poorer prognosis, suggesting a potential role in cisplatin resistance.
- Further research with larger cohorts is needed to validate CD2 as a predictive marker for cisplatin resistance in GCTs.
